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INTRODUCTION
Ankylosing spondylitis (AS), a type of spondyloarthritis, is a chronic systemic rheumatic inflammatory disease of the axial skeleton, large peripheral joints, and entheses [1] . The principal feature of AS is inflammation of the sacroiliac joint at the base of the spine followed by rising inflammation along the spine, resulting in back pain and stiffness [2] .
The standard of care for AS includes drugs such as non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), and non-drug interventions such as physical therapy. Although these drugs may offer palliation of symptoms, including spinal pain, peripheral joint pain, and physical function [1, 3] , none has been shown to alter the progression of AS.
AS is associated with significant direct medical costs in terms of medication, outpatient visits, hospitalizations, and alternative treatments [4] . In addition, given the progressive nature of AS and the related loss of functional ability, it leads to an increase in work disability and loss of productivity, particularly for individuals who undertake manual work [5] . Hence, AS is associated with a significant economic burden on both patients and society [3, 6] . Effective treatment interventions can reduce the severity of the disease and increase patients' physical function and overall quality of life, while also improving work capacity and productivity [7] .
Targeted biologic therapies have revolutionized the clinical management of AS.
Currently, five different tumor necrosis factor (TNF)-a inhibitors including adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab are approved for the treatment of active AS (an infliximab biosimilar has also been approved, but is not currently marketed in the US). Secukinumab, an interleukin-17 inhibitor, was recently approved by the Food and Drug Administration (FDA) for the treatment of active AS [8] . Clinical trials have shown that these agents produce clinically important benefits to patients by improving physical functioning and reducing disease activity [9] [10] [11] [12] [13] . A previous meta-analysis synthesized data of different agents and concluded that TNF-a blockers improve disease activity and functional capacity for AS [14] .
However, few head-to-head studies have directly compared the efficacy of these agents, and the comparative effectiveness among different biologic agents for AS treatment, especially for newer agents such as certolizumab pegol and secukinumab, is not well understood. Reliable evidence about the comparative effectiveness of these therapies is important to inform clinical and economic decisions regarding their use.
To fill these gaps, indirect comparisons of treatment outcomes across separate randomized trials can be used to provide valuable comparative evidence. Network meta-analysis is an approach that synthesizes information from several randomized comparisons to deliver internally consistent estimates of the treatment effects among competing interventions, while maintaining the randomization within each trial [15, 16] . Detailed methodological reviews and implementation guidelines for network meta-analyses have been published [15, [17] [18] [19] , and network meta-analyses have become a preferred source of comparative evidence for researchers, health-care decision makers, and health technology assessment agencies [15, 20, 21] .
The objective of this study was to determine the relative efficacy of the six approved biologic agents for active AS using a network meta-analysis, and to evaluate the incremental cost per responder for these agents over a 12-week treatment period.
METHODS

Trial Identification
Phase The study selection process was performed by two independent researchers with disagreements resolved by a third researcher. Data abstraction was performed by two independent researchers using a standardized data abstraction form.
Efficacy Measures
The ASAS criteria, the primary outcome in most AS trials, was used to define response [23] . has noted that the higher improvement of ASAS40 may be a more appropriate endpoint to evaluate biologic therapies [24] , and ASAS40 may be associated with clinical meaningful improvements in health-related quality of life [25] . For the purpose of analysis, outcomes were evaluated at week 12 (when week 12 outcomes were not available, outcomes reported at week 14 or week 16 were substituted for the week 12 outcomes).
Costs
This study was conducted from a US payer perspective, and only biologic drug acquisition costs and associated administration costs were considered in the analysis. Unit drug costs as of for the initial hour and 96,415 for subsequent hours [27] ). Infusion of infliximab was assumed to take 4 h [27, 28] .
Statistical Methods
A network meta-analysis was conducted to assess the comparative efficacy of the six approved biologic agents for the treatment of active AS.
The network meta-analysis was conducted within a Bayesian approach, as this approach can deliver both statistical estimations and a framework for probabilistic decision-making under uncertainty [16] . Using a random effects model, the number of people achieving an ASAS20 (or ASAS40) response at Week 12-16 was assumed to follow a binomial likelihood, with the corresponding probabilities being related to the treatment effects via a logit link function. Assessment of the goodness-of-fit and model diagnostics was based on the residual deviance and the deviance information criterion.
Non-informative priors were applied to ensure that treatment comparisons were driven by the observed data. Estimated comparative effects were summarized using posterior medians and 95% credible intervals (CrI). Numbers needed to treat (NNT) for each additional ASAS20 or ASAS40
responder were calculated as the reciprocal of the response rate difference between the agent and placebo. The incremental cost per responder for each treatment was calculated as the product of the 12-week costs and the NNT. Given that the efficacy measures from the clinical trials are based on intent-to-treat (ITT) analysis, the incremental costs per responder calculated in this study are also based on the ITT population. All analyses were conducted using Bayesian Markov chain
Monte Carlo (MCMC) with OpenBUGS 3.2.3 [16] .
Compliance with Ethics Guidelines
This article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS
The targeted literature review identified 15 trials that met the inclusion criteria and reported ASAS20 and/or ASAS40 response rates from Week 12 to Week 16 after initiation of treatment (Table 1) . Fourteen trials were placebo-controlled and one trial directly compared etanercept and infliximab [29] .
Among the 14 placebo-controlled trials, adalimumab was investigated in 3 trials [9, 30, 31] , certolizumab pegol in 1 trial [10] , etanercept in 4 trials [11, [32] [33] [34] , golimumab in 2 trials [12, 35] , infliximab in 2 trials [13, 36] , and secukinumab in 2 trials [37] . Figure 1 shows the evidence network of this study. All trials included were considered high quality, in terms Infliximab had a probability of 76% of having the highest ASAS20 response among all comparators, followed by adalimumab with a 9% probability, and golimumab with a 5% probability (Fig. 2a) . Adalimumab had a probability of 38% of having the lowest cost per ASAS20 responder among all comparators, followed by etanercept with a 22% probability, infliximab with a 21% probability, and golimumab with a 14% probability (Fig. 2b) .
Detailed results of the network meta-analysis of ASAS20 for all agents are shown in Table 2 .
Network Meta-Analysis: ASAS40
Patients with AS treated with infliximab had the highest probability of achieving ASAS40 (51.5%; ($48,547-$144,191). Adalimumab had a probability of 56% of having the lowest cost per ASAS40 responder among all comparators, followed by infliximab with a 17% probability, etanercept with a 14% probability, secukinumab without a loading dosage with a 7% probability, and golimumab with a 6% probability. Detailed results of the network meta-analysis of ASAS40 for all agents are shown in Table 3 .
DISCUSSION
The primary goal of AS treatment is to relieve symptoms, maintain physical function, and prevent complications [1] . The assessment in ankylosing spondylitis (ASAS) group recommended that physical function, spinal pain, patient global assessment, and Fig. 2 Ranking probabilities of biologic agents for treatment of active ankylosing spondylitis. a Ranking probabilities in ASAS20 response. b Ranking probabilities in cost per ASAS20 responder inflammation to be the core set of criteria to evaluate AS treatment response, and used them to construct composite criteria for use in AS trials [38] . ASAS20 and ASAS40 are among these composite criteria, which have been validated in previous studies of TNF blockers and are widely used in AS clinical trials [39] . In the current network meta-analysis of biologic treatments for active AS, infliximab had the lowest NNT to achieve an additional ASAS20/40 response, and adalimumab had the lowest 12-week cost per ASAS20/40 responder.
Previous research has assessed the efficacy of different biologic agents in the treatment of AS using conventional pairwise meta-analyses. One study compared adalimumab, etanercept, and infliximab with placebo, and found that these TNF inhibitors had significantly better efficacy than placebo, in terms of pain, physical function, patient's global assessment, and acute phase reactants [40] ASAS20 assessment in ankylosing spondylitis 20% response, CrI credible interval, NNT number needed to treat, OR odds ratio Efficacies were estimated based on a random effects network meta-analysis using a binomial model a Certolizumab pegol 200 mg every 2 weeks and 400 mg every 4 weeks were treated as equivalent therapeutic doses b Etanercept 25 mg twice a week and 50 mg every week were treated as equivalent therapeutic doses c Drug cost of infliximab was based on an 80 kg adult d Assumes that the efficacy of secukinumab 150 mg was equivalent with and without a loading dose Care Excellence (NICE) assessed data from sixteen randomized clinical trials via a network meta-analysis and compared the efficacy of adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab in the treatment of AS [43] . The results in the NICE report are in line with the ones presented in this study, in terms of both ASAS20 and ASAS40
(that report did not include data regarding the newer agent secukinumab). The current analyses are the first to compare the efficacy and cost-effectiveness among a comprehensive list of novel biologic agents for active AS treatment. This study indicated that adalimumab had the lowest overall cost per responder in the treatment of active AS (when considering both ASAS20 and ASAS40 response), which is consistent with previous studies regarding the cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis [44, 45] . previous TNF inhibitor exposure limited the ability to conduct the analysis in a pure TNF-naïve population. As the proportion of patients with prior TNF exposure is relatively small and the exposure would affect both the placebo and the active agent, the results are unlikely to be markedly affected by the inclusion of TNF-experienced patients for certolizumab pegol and secukinumab.
CONCLUSIONS
The current analyses are the first to compare the efficacy and cost-effectiveness among all available biologic agents for the treatment of active AS. In these analyses, adalimumab and infliximab demonstrated higher efficacy and lower cost per responder in terms of both ASAS20 and ASAS40. The study results indicate the potential for these agents to be used more cost-effectively in the treatment of active AS.
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